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Gonorrhea is among the most prevalent
sexually transmitted diseases throughout much
of the world. The emergence of resistance to anti-
microbial agents in Neisseria gonorrhoeae is a
major obstacle in the control of gonorrhea. In
1989 and 1993, in response to the increasing
frequency of isolation of penicillin-, tetracycline-,
and spectinomycin-resistant strains of  N. gonor-
rhoeae in the United States, the Centers for
Disease Control and Prevention (CDC) recom-
mended the use of broad-spectrum cephalosporins
or fluoroquinolones for the primary treatment of
uncomplicated gonorrhea (1,2). However, resis-
tance to fluoroquinolones has now emerged in  N.
gonorrhoeae (3-8). Because ciprofloxacin and
ofloxacin are more frequently used to treat
gonorrhea than other fluoroquinolones, this
synopsis will focus on these agents.
Fluoroquinolone Therapeutic Regimens,
Therapy Failure, and Susceptibility Tests
In 1993, CDC recommended single-dose,
oral therapy with ciprofloxacin (500 mg) or
ofloxacin (400 mg) as two of the primary
regimens for the treatment of uncomplicated
gonorrhea (2). Enoxacin (400 mg), lomefloxacin
(400 mg), and norfloxacin (800 mg) were recom-
mended among alternative regimens (2). In some
countries, gonococcal infections have been treated
with a single, orally administered dose of 250
mg ciprofloxacin (8). The failure of gonococcal
infections to respond to treatment with 250 mg
ciprofloxacin has been reported in the United
Kingdom since 1990 (8-11). The failure of infec-
tions to respond to single-dose therapy with 500
mg ciprofloxacin or 400 mg ofloxacin has been
reported in the United Kingdom, Australia, Canada,
Hong Kong, and the United States (3-7,12).
Different methods for determining in vitro
antimicrobial susceptibilities of N. gonorrhoeae
have been developed in several countries. Dif-
ferences between these methods—the medium
on which the susceptibilities are determined,
the concentrations of antimicrobial agents tested,
the concentration of antimicrobial agents in
disks used to determine zone inhibition diameters,
or the inoculum size—complicate the inter-
pretation of susceptibility test results. For
example, in the United Kingdom, Australia,
and Hong Kong, susceptibilities are usually
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determined on Isosensitest medium (Oxoid,
Basingstoke, United Kingdom) (3,8,13-15). In the
United States (where criteria for interpreting
susceptibilities of  N. gonorrhoeae are established
by the National Committee for Clinical Laboratory
Standards [NCCLS]) and Canada, susceptibilities
are determined on a Difco or Becton Dickinson
base medium (Difco Laboratories, Detroit, MI;
Becton Dickinson, Cockeysville, MD) (16-19).
Antimicrobial susceptibilities determined on Oxoid
base medium may be one concentration lower
than those determined on supplemented Difco or
Becton Dickinson base media (15). Neither
method is right or wrong; nor is one method
better than the other; they are different. The
method used in different countries is influenced
by the commercial availability of the base medium.
Thus, criteria for interpreting susceptibilities in
the United States and Canada may differ slightly
from those used to interpret susceptibilities in
the United Kingdom, Australia, and Hong Kong,
reflecting the difference in susceptibilities obtained
on different media. Similarly, when suscep-
tibilities are measured on media different from
those described above it may be necessary to
establish “local” criteria using reference strains
with known susceptibilities.
Gonococcal strains associated with therapy
failure to 250 mg ciprofloxacin have had mini-
mum inhibitory concentrations (MICs) of ‡0.06 to
0.25 µg/ml of ciprofloxacin (8,11); posttreatment
strains from infections that failed to respond to
treatment with 500 mg ciprofloxacin or 400 mg




Before the emergence of fluoroquinolone
resistance in  N. gonorrhoeae, NCCLS established
interpretive criteria to differentiate between
susceptible strains and those exhibiting decreased
susceptibility to selected fluoroquinolones inclu-
ding ciprofloxacin, ofloxacin, lomefloxacin, and
enoxacin (16,17). Criteria for the interpretation
of clinically significant resistance of gonococcal
strains to 500 mg ciprofloxacin and 400 mg
ofloxacin have been proposed (6,18).
Criteria for interpreting susceptibilities of
N. gonorrhoeae to antimicrobial agents should be
based on treatment outcome and strain suscep-
tibility data. However, because many infections
caused by fluoroquinolone-resistant strains were
treated with broad-spectrum cephalosporins and
few observations linked fluoroquinolone therapy
outcome and antimicrobial susceptibilities (MICs),
CDC proposed criteria for interpreting fluoro-
quinolone resistance in N. gonorrhoeae that were
based on theoretical predictions of the MICs at
which gonococcal infections may fail to respond to
CDC-recommended doses of selected fluoro-
quinolones (18). On the basis of the therapeutic
index (calculated by dividing the peak level of the
agent in serum by the MIC of the infecting
strain), CDC proposed criteria for interpreting
susceptibilities to selected fluoroquinolones
(Table) (18,20). These criteria were consistent
with the MICs of isolates from the observed
treatment failures to 500 mg ciprofloxacin and
400 mg ofloxacin documented at the time of the
study (4,5,12). Recently, Kam et al. proposed
interpretive criteria based on the susceptibilities
of many strains that did not respond to treatment
with ofloxacin in Hong Kong (Table) (6). CDC and
Kam et al. proposed identical MICs for inter-
preting resistance to ciprofloxacin and ofloxacin:
MICs of ‡2.0 µg/ml and ‡1.0 µg/ml of ofloxacin
and ciprofloxacin, respectively. These criteria
have also been adopted in Australia (15).
In the United Kingdom, where 250 mg cipro-
floxacin has been used to treat gonorrhea, strains
with MICs of 0.06 to 0.25 µg/ml have been isolated
from infections that did not respond to treatment
(8,11). Ciprofloxacin in a 250-mg dose produces a
peak serum level of approximately 1.2 µg/ml;
thus, strains with MICs of ‡0.25 to 0.5 µg/ml
would produce therapeutic indices of 4.8:1 and
2.4:1, respectively. These calculated MICs sug-
gest that strains with MICs ‡0.25 µg/ml should
be considered resistant to treatment with 250 mg
ciprofloxacin. Criteria for interpreting suscep-
tibilities of gonococcal strains to treatment with
250 mg ciprofloxacin have been determined to
ciprofloxacin (1 µg disks) or nalidixic acid (30 µg
disks) (10,21). Measurement of nalidixic acid
resistance may be useful for detecting strains
causing infections that may not respond to treat-
ment with 250 mg ciprofloxacin. However, because
naladixic acid-resistance indicates decreased
susceptibility to ciprofloxacin and ofloxacin, this
test does not differentiate between strains with
intermediate resistance and clinically significant
resistance to treatment with 500 mg ciprofloxacin
or 400 mg ofloxacin (18).35 Vol. 3, No. 1—January-March 1997 Emerging Infectious Diseases
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Geographic Distribution, Frequency,
and Diversity of Fluoroquinolone-
resistant N. gonorrhoeae
Strains exhibiting intermediate resistance
(MICs 0.125 to 0.5 µg/ml of ciprofloxacin; MICs
0.5-1.0 µg/ml of ofloxacin) have been reported
from many geographic areas including Australia,
Canada, the Canary Islands, Hong Kong, Japan,
the Republic of the Philippines, mainland Spain,
Thailand, the United Kingdom, the United States,
and the West Indies (4,7,9-15,21-32). Fluoro-
quinolone resistance (MICs of ‡1.0 µg/ml or
‡2.0 µg/ml of ciprofloxacin or ofloxacin, respec-
tively) has been reported most frequently from
the Far East, Republic of the Philippines, Hong
Kong, Japan) and less frequently from Australia,
Canada, Spain, Thailand, United Kingdom, and
the United States (3,4,6,7,9,12,15,22-32). Ofloxacin-
and ciprofloxacin-resistant strains had been
isolated sporadically in Hong Kong, the Republic
of the Philippines,  and Thailand for some years
(22-24). The frequency of fluoroquinolone-resistant
strains has increased dramatically since the
early 1990s. For example, in Hong Kong, fluoro-
quinolone-resistant strains were isolated inter-
mittently during 1990 to 1992 (13) but have
increased dramatically from an estimated 0.5%
in late 1992 to 10.4% in late 1994 (14).
From 1994 to 1995, strains exhibiting
decreased susceptibility to ciprofloxacin and
ofloxacin accounted for approximately 36%, 54%,
and 22% of strains in Hong Kong, the Republic of
the Philippines, and Thailand, respectively
(13,14,29,31,32). During the same period,
fluoroquinolone-resistant strains accounted for
approximately 10%, 12%, and 1% of all strains in
Hong Kong, the Republic of the Philippines, and
Thailand, respectively (13,14,29,31,32). Strains
with ciprofloxacin MICs of ‡8.0 µg/ml were first
isolated in 1994 (10,12,29,31).
In other geographic areas, strains exhibiting
intermediate resistance and resistance have
been isolated only sporadically, although with
increasing frequency. In Sydney, Australia,
fluoroquinolone-resistant strains were isolated
infrequently in 1991 to 1994, but with drama-
tically increasing frequency in early 1995 (15).
The pattern of isolation of fluoroquinolone-
resistant strains in Australia, i.e., infrequent and
sporadic isolations for a number of years followed
by increasing frequency of isolation over a short
period, may be anticipated in other countries
unless the fluoroquinolone-resistant strains are
controlled in the Far East, where they are now
prevalent. In the CDC-sponsored Gonococcal
Isolate Surveillance Project in the United States,
the frequency of strains with intermediate resis-
tance has increased significantly from 0.3%
(17/5,238) in 1991 to 1.3% (65/4,996) in 1994
(p £ 0.001); however, resistant strains accounted
for only 0.04% (2/4,996) of strains in 1994 (33,34).
In the United States, the increase in strains with
intermediate resistance is associated largely, but
not exclusively, with the persistence of such
strains in Cleveland, Ohio. First detected in
1992, these strains accounted for 16% to 17.5% of
isolates in Cleveland in 1994 (26,35). In addition,
a sustained outbreak caused by ciprofloxacin-
resistant strains has been reported from Seattle,
Washington, in 1995; these strains had MICs of
8.0 µg/ml of ciprofloxacin and ofloxacin (5).
Table. Criteria for interpreting susceptibilities of Neisseria gonorrhoeae strains to the fluoroquinolones ciprofloxacin,
ofloxacin, enoxacin, lomefloxacin, and norfloxacina,b
Therapeutic agent, Agent Tested, Zone Inhibition Diametersc Equivalent MICc (mg/ml) Reference
Dose Disk Content nearest whole mm
(mg) R I S R I S
Ciprofloxacin, 250 mg Cip, 1 £24 ‡0.03   8
Ciprofloxacin, 500 mg Cip, 5 £29 30-35 ‡36 ‡1.0 0.13-0.5 £0.06 18
Cip, 5 £22 ‡1.0   6
Ofloxacin, 400 mg Ofx, 5 £24 25-30 ‡31 ‡2.0 0.5-1.0 £0.25 18
Ofx, 5 £24 ‡1.0   6
Enoxacin, 400 mg Enx, 10 £31 ‡32 ‡1.0      0.5 £0.25 18
Lomefloxacin, 400 mg Lom, 10 £26 27-35 ‡36 ‡2.0 0.25-1.0 £0.125 18
Norfloxacin, 800 mg Nor, 5 £32 33-35 ‡36 ‡1.0      0.5 £0.25 18
aThese criteria have not been recommended by the National Committee for Clinical Laboratory Standards (NCCLS); they are
provided to guide interpretation of susceptibilities until the NCCLS establishes criteria.
bAbbreviations: MIC, minimal inhibitory concentration (mg/ml); R, resistant; I, intermediate resistance; S, susceptible; Cip,
ciprofloxacin; Ofx, ofoxacin; Enx, enoxacin; Lom, lomefloxacin; Nor, norfloxacin.
cWith the exception of norfloxacin, criteria for the susceptible categories are those designated by the NCCLS (16,17); criteria for
the interpretation of the susceptible category for norfloxacin were proposed by CDC (18).36 Emerging Infectious Diseases Vol. 3, No. 1—January-March 1997
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Many different strains, as defined by
penicillin/tetracycline resistance phenotype and
auxotype/serovar (A/S) class, exhibit intermediate
resistance and resistance to fluoroquinolones
(4,5,15,25,26,31,32,36). Fluoroquinolone resistance
has been identified frequently in strains that
produce ß-lactamase and strains exhibiting chro-
mosomally mediated resistance to penicillin and
tetracycline and less frequently in strains that
are susceptible to penicillin and tetracycline
(4,31,32). Fluoroquinolone resistance has not
been documented in strains possessing the 25.2-
megadalton TetM-containing plasmid (TRNG)
alone or in TRNG strains possessing a ß-lactamase
plasmid (31). It should not, however, be assumed
that these strains may not develop fluoroquinolone
resistance, but rather that resistant strains have
not been detected at this time. Many strains, as
defined by A/S class, are associated with fluoro-
quinolone resistance; fluoroquinolone resistance
is not associated with the epidemic spread of one
or two strains (15,31,32). In Australia, strains
exhibiting intermediate resistance and resistance
to fluoroquinolones have belonged to 27 different
A/S classes; strains with MICs 8.0-16.0 µg/ml of
ciprofloxacin have belonged to 6 A/S classes (15).
In the Republic of the Philippines, strains belong-
ing to 27 A/S classes exhibited decreased suscepti-
bility to ciprofloxacin; strains belonging to 10 A/S
classes had MICs ‡1.0 µg/ml of ciprofloxacin (31).
In Thailand, strains belonging to 13 A/S classes ex-
hibited decreased susceptibility to ciprofloxacin (32).
The Gonococcal Isolate Surveillance Project
monitors the susceptibilities of N. gonorrhoeae
isolates to fluoroquinolones in the United States
and provides prototype reference strains for
quality assurance of susceptibility testing of
these agents. Information about antimicrobial
resistance in  N. gonorrhoeae in the United
States is available on the Internet at http://
www.cdc.gov/ncidod/dastlr/gcdir/gono.html.
Mechanisms of Resistance to
Fluoroquinolones
 Fluoroquinolones inhibit the replication of
DNA; they are believed to bind to the GyrA region
of DNA gyrase, which is attached to DNA, and
inhibit the enzyme from supercoiling the DNA
(37). Resistance to fluoroquinolones in N. gonor-
rhoeae is associated with mutations that result in
amino acid changes in the A subunit (GyrA) and
the B subunit (GyrB) of the DNA gyrase, and in
the parC-encoded subunit of topoisomerase IV
(37-40). Although mutations in gyrB confer low-
level resistance to naladixic acid, high-level
quinolone resistance is associated with mutations
in the quinolone resistance-determining region of
gyrA (41). Topoisomerase IV, encoded by parC
and  parE in  Escherichia coli and believed to be
located in the cytoplasmic membrane, is involved
in DNA replication but is not as sensitive to
fluoroquinolone inhibition as is DNA gyrase (37).
No parE analog has been detected in N.
gonorrhoeae (37). Mutations in gyrA and parC
are most relevant when considering clinically
significant levels of fluoroquinolone resistance in
N. gonorrhoeae (37,39,40). Similar results have
been obtained in studies of gyrA mutations in both
laboratory-adapted strains and clinical isolates
(37,39,40): ciprofloxacin-susceptible strains
(MICs, <0.03 µg/ml) had no mutations in gyrA
and strains with MICs, ‡0.5 µg/ml of ciprofloxacin
may have changes in nucleotides 272 and 283 of
gyrA. In addition, strains with MICs ‡2.0 had
mutations in  parC. Mutations in  parC were
observed only in strains with at least one muta-
tion in gyrA (37,39) and appeared to be associated
with an MIC higher than would be expected with
the gyrA mutation alone (39). Mutations in gyrA
and  parC may be characterized by polymerase
chain reaction and DNA sequencing (37,39). The
transfer of gyrA and parC mutations between
gonococcal strains has been demonstrated in vitro
(37). The presence of transformation sequences
just downstream from the gyrA sequences sug-
gests that transformation may play a role in the
spread of gyrA mutations between gonococcal
strains in vivo (37). The opportunity for trans-
formation of genes between gonococcal strains,
which depends on concurrent infections with
multiple strains, has been documented for women
and homosexual men (42,43).
In addition to mutations in  gyrA and  parC,
reduced permeability of the cytoplasmic mem-
brane may contribute to low-level resistance to
fluoroquinolones in  N. gonorrhoeae, e.g., increasing
the MIC of one recipient strain from £0.002 to
0.06 µg/ml of ciprofloxacin (3,44). This resistance
may also be transferred between gonococcal strains
by transformation (3).
Guidance
Continued reports of the isolation of fluoro-
quinolone-resistant strains of N. gonorrhoeae
indicate the need for heightened awareness of the
potential for increasing prevalence of strains with37 Vol. 3, No. 1—January-March 1997 Emerging Infectious Diseases
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clinically significant fluoroquinolone resistance.
In areas where a fluoroquinolone is used to treat
gonorrhea, the following steps are recommended
to monitor and control the spread of fluoro-
quinolone-resistant strains of N. gonorrhoeae.
• Susceptibility testing should be performed to
detect fluoroquinolone resistant strains. In
geographic areas where interpretive criteria
have not been proposed, criteria should be
developed for results obtained with local test
procedures that use strains with known sus-
ceptibilities to ciprofloxacin or ofloxacin.
• Ideally, routine surveillance for emerging
fluoroquinolone resistance should be per-
formed in centers where fluoroquinolones are
used widely to treat gonorrhea; e.g., a sample
of approximately 20 to 50 consecutive isolates
should be tested periodically. If ciprofloxacin-
resistant isolates are detected, the use of
alternative therapies for gonorrhea should be
considered; if isolates are ciprofloxacin-
susceptible, ciprofloxacin or ofloxacin may be
used to treat gonorrhea.
• Susceptibilities of isolates from individual
patients whose infections did not respond
to treatment with a fluoroquinolone should
be determined.
• A cluster of infections unresponsive to fluoro-
quinolone therapy may indicate an outbreak
caused by a resistant strain.
• If treating gonorrhea with a fluoroquinolone,
e.g., ciprofloxacin or ofloxacin, never use less
than the recommended dose. In the United
States, 500 mg of ciprofloxacin or 400 mg
ofloxacin should be used.
• Because gonococcal infections caused by
fluoroquinolone-resistant strains have been
acquired frequently in the Far East, clini-
cians may wish to treat infections possibly
acquired in the Far East with 125 mg ceftri-
axone, intramuscularly, or 400 mg cefixime,
orally, the current CDC-recommended doses
for treating gonococcal infections.
The importance of the emergence and spread
of fluoroquinolone resistance in N. gonorrhoeae
cannot be overstated. Of antimicrobial agents
available for treating gonorrhea, broad-spectrum
cephalosporins are the only agents to which  N.
gonorrhoeae is not  resistant, and exclusive use of
these agents, particularly the orally administered
cephalosporins such as cefixime, may result
ultimately in the emergence of resistance to these
agents. Thus, it is critical to take measures to
ensure that fluoroquinolones remain effective for
the treatment of uncomplicated gonorrhea for as
long as possible.
Dr. Knapp is chief, Gonorrhea, Chlamydia, and Chan-
croid Branch, Division of AIDS, STD, and TB Laboratory
Research, National Center for Infectious Diseases, CDC.
Her research interests are antimicrobial resistance in N.
gonorrhoeae, the molecular epidemiology of gonococcal
strain populations, and the taxonomy of Neisseria spp.
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